HCPS | Jotup

Neuronetics Launches Upgrades of NeuroStar® Advanced Therapy for Mental Health

Tuesday, October 19, 2021 - 1:31pm

MALVERN, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders announced today the release of the latest evolution of their NeuroStar® Advanced Therapy system with upgraded equipment and features. NeuroStar® Advanced Therapy for Mental Health is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over 4 million treatments delivered and thousands of lives transformed. In addition to a refreshed look, the NeuroStar and TrakStar® enhancements will allow healthcare professionals (HCPs) to streamline their ability to treat more patients.

Key Points:

NeuroStar Advanced Therapy for Mental Health is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over 4 million treatments delivered and thousands of lives transformed.
A limited release will occur with specific TrakStar Cloud customers in mid-October with a full release to follow in the U.S.
To learn more about NeuroStar Advanced Therapy, visit www.neurostar.com .
Neuronetics, Inc. believes that mental health is as important as physical health.
An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics NeuroStar Advanced Therapy system is todays leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults with over four million treatments delivered.

Insight Consulting Group Awarded Market Research Agreement with Premier Inc.

Tuesday, October 19, 2021 - 12:57pm

Insight Consulting Group (ICG) has been awarded a group purchasing agreement for Market Research services with Premier Inc., a nationwide healthcare group purchasing organization with 4,400 U.S. hospitals and 225,000 other provider members.

Key Points:

Insight Consulting Group (ICG) has been awarded a group purchasing agreement for Market Research services with Premier Inc., a nationwide healthcare group purchasing organization with 4,400 U.S. hospitals and 225,000 other provider members.
This new agreement allows Premier members, at their discretion, to take advantage of special ICG pricing and terms pre-negotiated by Premier to help members make better business decisions through advanced qualitative and quantitative research solutions and strategy development.
According to Chris Schnaars, Principal at Insight Consulting Group (ICG), Our agreement with Premier gives its members access to research services to better understand and meet the changing needs of patients.
Regardless of the sector a Premier member belongs to health network, hospital, group practices or members outside of healthcare ICGs research services empower members to fast-track and optimize the insights process.

COVID-19 Battering Healthcare Workers with 1 in 3 Battling Depression as Pandemic Rages, CulturIntel Study Finds

Friday, October 15, 2021 - 12:33pm

DALLAS, Oct. 15, 2021 /PRNewswire/ --One in three healthcare workers are battling depression and more than 73% report feeling negative about their mental state because of the ongoing COVID-19 pandemic, according to Voices of Healthcare Heroes, a new study from CulturIntel released today.

Key Points:

DALLAS, Oct. 15, 2021 /PRNewswire/ --One in three healthcare workers are battling depression and more than 73% report feeling negative about their mental state because of the ongoing COVID-19 pandemic, according to Voices of Healthcare Heroes, a new study from CulturIntel released today.
For example, the study reveals that physicians are experiencing 1.8 times more anger than the overall population, whereas overall healthcare workers are feeling 1.6 times more traumatized than the overall population.
The effect of the pandemic is heightened for healthcare workers as they are not seeing the light at the end of the tunnel and report facing too many challenges to move forward.
Despite these challenges, healthcare workers also report being three times more driven by purpose and camaraderie among their community.

Keen360 Released Keen Life Sciences for Pharma, Biotech & Medical Device Industries to Extend Creatio's No-code Platform Capabilities

Creatio, Time-invariant system, Industry, Keen, Compliance, CRM, SFDC, BPM, Mobility, HCPS, Marketing, Affiliate marketing, Internationalized domain name, List of life sciences, HCP, HCO, Fine chemical

Thursday, October 14, 2021 - 1:44pm

The pre-configured application offers enterprise-caliber functionality and security, extending the no-code Creatio platform capabilities to allow professionals engaged in commercial operations in the life sciences industry to power-up their day-to-day operations.

Key Points:

The pre-configured application offers enterprise-caliber functionality and security, extending the no-code Creatio platform capabilities to allow professionals engaged in commercial operations in the life sciences industry to power-up their day-to-day operations.
Keen Life Sciences is well suited for both well-established companies that are relying on mature commercial teams and rapidly-growing ventures that areemerging from clinical trials and launching their commercial teams.
The solution offers the full range of functionality usually found in the complex and expensiveapplications that are built on the SFDC platform.
Key Keen Life Sciences features:
HCO & HCP profiles:capture and maintain the range of domain-specific information about your HCOs and HCPs.

New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma

Wednesday, October 13, 2021 - 11:10am

Every patient is unique, and this new indication means SARCLISA has the potential to benefit a wide variety of Canadians living with multiple myeloma."

Key Points:

Every patient is unique, and this new indication means SARCLISA has the potential to benefit a wide variety of Canadians living with multiple myeloma."
This approval marks the second indication for SARCLISA in combination with a standard of care regimen for the treatment of relapsed and/or refractory MM.
Previously, SARCLISA received Health Canada approval in combination with another standard of care regimen, pomalidomide and dexamethasone (Pd), for the treatment of adult patients with relapsed and refractory MM who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
These findings strengthen our confidence in isatuximab in the relapsed and refractory setting and demonstrate that isatuximab is becoming a standard of care in this environment."

PatientPoint Launches Additional Specialty Programs to Further Accelerate Growth in 2022

Trajectory, Therapy, Pediatrics, HCPS, Multimedia, Urology, Patient, Growth, Outcome Health, Industry, Medicine, Pharmaceutical industry

Thursday, October 7, 2021 - 7:00pm

The company will also be announcing several additional high-impact specialty launches in the coming weeks.

Key Points:

The company will also be announcing several additional high-impact specialty launches in the coming weeks.
PatientPoint engagement platform now reaches 140K unique HCPs in 18 specialties, additional specialty launches planned.
"Our expansion into additional specialties will help more specialists engage with patients with complex or difficult-to-treat conditions across their entire path of treatment."
"One out of every three scripts is written by a PatientPoint provider for most therapeutic areas," said Collette.

Steve Kurzeja Named Chief Revenue Officer of Life Sciences Tech Innovator P360

Wednesday, October 6, 2021 - 2:29pm

P360 , a leading developer of technology for life sciences companies, today announced that veteran pharmaceutical industry executive Steve Kurzeja was appointed the companys first chief revenue officer (CRO).

Key Points:

P360 , a leading developer of technology for life sciences companies, today announced that veteran pharmaceutical industry executive Steve Kurzeja was appointed the companys first chief revenue officer (CRO).
View the full release here: https://www.businesswire.com/news/home/20211006005006/en/
P360 Chief Revenue Officer Steve Kurzeja (Photo: Business Wire)
Steves vast experience leading revenue-generating initiatives for pharmaceutical companies makes him the perfect fit to serve as chief revenue officer of P360, stated P360 CEO and Founder Anupam Nandwana.
I am thrilled to be joining such an innovative and passionate group of industry disruptors, said P360 Chief Revenue Officer Steve Kurzeja.
The appointment of Steve Kurzeja as chief revenue officer comes just as P360 announced that its ZING Communication Module has been enhanced with several new enterprise-grade unified communication features.

Aktana Launches Contextual Intelligence 360 to Solve the Challenge of Personalizing Customer Engagement at Scale

Wednesday, October 6, 2021 - 12:26pm

Contextual Intelligence 360 builds on Aktanas legacy AI strength in sales channel optimization to bring the same level of machine learning precision and contextual insights to all commercial activities.

Key Points:

Contextual Intelligence 360 builds on Aktanas legacy AI strength in sales channel optimization to bring the same level of machine learning precision and contextual insights to all commercial activities.
Now, as the use of digital is skyrocketing and HCPs are time-constrained like never before, coordinated omnichannel engagement with HCPs is crucial for success.
Aktanas Contextual Intelligence 360 includes the following components:
HCP Engagement AI Pre-built machine learning modules dynamically identify individual customer preferences across content, channel, and timing.
Today, commercial and medical teams from nearly 300 brands use Aktanas AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale.

Aktana Launches Next Generation of its Contextual Intelligence Engine to Accelerate Enterprise-Wide AI Adoption

Adoption, Partnership, CIE, Solution, HCPS, Logic, Suggestion, Health, AI, SAN, Organization, Investment, HCP, Industry, Theory of multiple intelligences, GLOBE, Management

Wednesday, October 6, 2021 - 12:24pm

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aktana , the leader in intelligent customer engagement for the global life sciences industry, today announced its Contextual Intelligence Engine (CIE) 2.0.

Key Points:

SAN FRANCISCO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aktana , the leader in intelligent customer engagement for the global life sciences industry, today announced its Contextual Intelligence Engine (CIE) 2.0.
The upgraded version of the CIE is designed specifically for two of the most urgent needs in life sciences commercial operations today: omnichannel optimization and AI flexibility.
Contextual Intelligence Engine 2.0 can work with any number of analytical models simultaneously to find the best combination of all possible activities, in all channels, by all members of the commercial team.
Today, commercial and medical teams from nearly 300 brands use Aktanas AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale.

Almirall S.A.: Experts highlight the need to focus on psoriasis patients' wellbeing in clinical practice

Wednesday, October 6, 2021 - 10:35am

", Prof. Piaserico (Italy) together with Prof. Mrowietz (Germany) and the happiness scientist Prof. Quoidbach (Spain), addressed questions on psoriasis patients' true needs and wellbeing.

Key Points:

", Prof. Piaserico (Italy) together with Prof. Mrowietz (Germany) and the happiness scientist Prof. Quoidbach (Spain), addressed questions on psoriasis patients' true needs and wellbeing.
The experts pointed out that, in addition to manage the disease's clinical manifestations, the clinical practice should implement an overall and holistic assessment of the wellbeing of each patient.
The overall wellbeing of a patient and the holistic approach of people-centred healthcare has never been measured in a robust prospective psoriasis study.
"Providing patients with real solutions that improve their health and wellbeing is at the core of everything we do at Almirall.